Fatal Lapses: Toxic Cough Syrups in India and Beyond
Indian pharmaceutical firms have risked children’s lives by not adhering to regulations. Faulty testing of toxic cough syrups, which killed 17 children recently and others abroad since 2022, has damaged India's drug-making reputation. Scrutiny and potential penalties loom as investigations continue.
Investigations into Indian pharmaceutical companies have revealed alarming lapses in their regulatory compliance, the country's drug regulator reported on Wednesday. This follows the recent tragic deaths of 17 children due to toxic cough syrups.
These incidents prompted further scrutiny, showing that certain firms had not adhered to mandatory testing protocols. The drug controller general confirmed checks were conducted, exposing firms linked to previously substandard quality drugs, yet their identities remain undisclosed.
With India's pharmaceutical industry under the spotlight, authorities are taking significant steps, including banning suspect medicines and considering severe actions against errant manufacturers. The global reputation of India's drug exports, vital to the global supply chain, hangs in the balance.
(With inputs from agencies.)
Google News